<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="urn:hl7-org:v3" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="32225bd7-54bb-93da-e063-6394a90aadc5"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use ULTRAVATE® Lotion safely and effectively.
 <br/>
See full prescribing information for ULTRAVATE Lotion.
 <br/>
      <br/>
ULTRAVATE (halobetasol propionate) lotion, for topical use
 <br/>
Initial U.S. Approval: 1990
</title>
   <effectiveTime value="20250406"/>
   <setId root="74e899db-1c1f-48b2-9913-5d32a14906ae"/>
   <versionNumber value="1"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id root="1.3.6.1.4.1.519.1" extension="117072266"/>
            <name>Lacer Pharma, LLC</name>
            <assignedEntity>
               <assignedOrganization>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="005320536"/>
                        <name>Ferndale Laboratories, Inc.</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C25391" displayName="analysis" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="73159-008" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" displayName="manufacture" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="73159-008" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" displayName="pack" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="73159-008" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84732" displayName="label" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="73159-008" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="33ea16d0-54f1-0622-e063-6294a90a5e09"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <effectiveTime value="20250406"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="73159-008" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>ULTRAVATE</name>
                        <formCode code="C29167" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="LOTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Halobetasol propionate</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="P7E6YFV72X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>DIISOPROPYL ADIPATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="461N1O614Y" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>OCTYLDODECANOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="I835H2IHHX" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CETETH-20</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="TUF2IVW3M2" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLOXAMER 407</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="936JST6JCN" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CETYL ALCOHOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="2KR89I4H1Y" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>STEARYL ALCOHOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="Z8IX2SC1OH" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>PROPYLPARABEN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3QPI1U3FV8" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>BUTYLPARABEN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="6DC9Q167V3" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>PROPYLENE GLYCOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="PDC6A3C0OX" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>GLYCERIN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="0A5MM307FC" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CARBOMER HOMOPOLYMER, UNSPECIFIED TYPE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="55X04QC32I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM HYDROXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>WATER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="0.5"/>
                              <denominator unit="g" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="91A0K1TY3Z" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HALOBETASOL PROPIONATE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="9P6159HM7T" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>HALOBETASOL</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="59" unit="g"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="73159-008-60" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20250406"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA208183" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20250406"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48325" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="white" xsi:type="CE">
                              <originalText>white to off-white</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38304" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TOPICAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="id_link_3222a0ff-9998-9941-e063-6394a90ae83e">
               <id root="3222a0ff-9997-9941-e063-6394a90ae83e"/>
               <code code="43683-2" codeSystem="2.16.840.1.113883.6.1" displayName="RECENT MAJOR CHANGES SECTION"/>
               <effectiveTime value="20250406"/>
               <excerpt>
                  <highlight>
                     <text>
                        <table width="100%">
                           <colgroup>
                              <col align="left" valign="top" width="60%"/>
                              <col align="right" valign="top" width="40%"/>
                           </colgroup>
                           <tbody>
                              <tr>
                                 <td align="left">Indication and Usage ( 
       <linkHtml href="#S1">1</linkHtml>)
      </td>
                                 <td align="right">08/2020</td>
                              </tr>
                              <tr>
                                 <td align="left">Warnings and Precautions (5.1)</td>
                                 <td align="right">08/2020</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph/>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S1">
               <id root="3222a05b-a0b7-59f9-e063-6294a90a16d1"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>ULTRAVATE lotion is indicated for the topical treatment of plaque psoriasis in patients 12 years of age and older.</paragraph>
                  <paragraph/>
               </text>
               <effectiveTime value="20250406"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>ULTRAVATE lotion is a corticosteroid indicated for the topical treatment of plaque psoriasis in patients 12 years of age and older. ( 
    <linkHtml href="#S1">1</linkHtml>)
   </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S2">
               <id root="32225bd7-54be-93da-e063-6394a90aadc5"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <text>
                  <paragraph>Apply a thin layer of ULTRAVATE lotion to the affected skin twice daily for up to two weeks. Rub in gently.</paragraph>
                  <paragraph>Discontinue therapy when control is achieved. If no improvement is seen within two weeks, reassessment of diagnosis may 
  <br/>  be necessary.
 </paragraph>
                  <paragraph>Treatment beyond two weeks is not recommended and the total dosage should not exceed 50 grams (50 ml) per week because of the potential for the drug to suppress the hypothalamic-pituitary-adrenal (HPA) axis {see Warnings and Precautions 5.1].Do not use with occlusive dressings unless directed by a physician.</paragraph>
                  <paragraph>ULTRAVATE lotion is for external use only.</paragraph>
                  <paragraph>Avoid use on the face, scalp, groin, or axillae.</paragraph>
                  <paragraph>ULTRAVATE lotion is not for ophthalmic, oral, or intravaginal use.</paragraph>
               </text>
               <effectiveTime value="20250406"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>Apply a thin layer to the affected areas twice daily. (2)</item>
                           <item>Limit use to 50 g/week. (2)</item>
                           <item>Discontinue treatment when control is achieved. (2)</item>
                           <item>If no improvement is seen within 2 weeks, reassess diagnosis. (2)</item>
                           <item>Treatment beyond 2 consecutive weeks is not recommended. (2)</item>
                           <item>Do not use with occlusive dressings unless directed by a physician. (2)</item>
                           <item>Avoid use on the face, scalp, groin, or axillae. (2)</item>
                           <item>Not for ophthalmic, oral, or intravaginal use. (2)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S3">
               <id root="32225bd7-54bf-93da-e063-6394a90aadc5"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph>ULTRAVATE (halobetasol propionate) lotion, 0.05% is a white to off-white lotion. Each gram of ULTRAVATE lotion contains 0.5 mg of halobetasol propionate.</paragraph>
               </text>
               <effectiveTime value="20250406"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Lotion: 0.05% (0.5 mg/g). (3)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S4">
               <id root="32225bd7-54c0-93da-e063-6394a90aadc5"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <paragraph>None.</paragraph>
               </text>
               <effectiveTime value="20250406"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>None.</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S5">
               <id root="32225bd7-54c1-93da-e063-6394a90aadc5"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20250406"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>Reversible hypothalamic-pituitary-adrenal (HPA) axis suppression may occur, with the potential for glucocorticosteroid insufficiency during or after treatment. Systemic absorption may require evaluation for HPA axis suppression. (5.1)</item>
                           <item>Systemic effects of topical corticosteroids may also include Cushing's syndrome, hyperglycemia, and glucosuria. Use of potent corticosteroids on large areas, for prolonged durations, under occlusive dressings, or on an altered skin barrier may increase systemic exposure. (5.1)</item>
                           <item>Children may be more susceptible to systemic toxicity when treated with topical corticosteroids. (5.1, 8.4)</item>
                           <item>Local adverse reactions with topical steroids may include atrophy, striae, irritation, acneiform eruptions, hypopigmentation, and allergic contact dermatitis. Adverse reactions may be more likely to occur with occlusive use or more potent corticosteroids. (5.2, 5.5)</item>
                           <item>Topical corticosteroids may increase the risk of cataract and glaucoma formation. If visual symptoms occur, consider referral to an ophthalmologist tor evaluation. (5.3)</item>
                           <item>Initiate appropriate therapy if concomitant skin infections develop. (5.4)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S5.1">
                     <id root="3223ca54-514b-ddfa-e063-6294a90a7bac"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1 Effects on Endocrine System</title>
                     <text>
                        <paragraph>ULTRAVATE lotion has been shown to suppress the hypothalamic-pituitary-adrenal (HPA) axis.Systemic effects of topical corticosteroids may include reversible HPA axis suppression, with the potential for glucocorticosteroid insufficiency. This may occur during treatment or upon withdrawal of treatment of the topical corticosteroid.The potential for hypothalamic-pituitary adrenal (HPA) suppression with ULTRAVATE lotion was evaluated in the following studies:</paragraph>
                        <list listType="unordered">
                           <item>In a study of 20 adult subjects with moderate to severe plaque psoriasis involving 􀃙20% of their body surtace area. ULTRAVATE lotion produced HPA axis suppression when used twice daily for two weeks in 5 out of 20 (25%) adult subjects with plaque psoriasis. The effects of HPA axis suppression were reversible on discontinuation of the treatment 
   <content styleCode="italics">[see Clinical Pharmacology (12.2)]</content>.
  </item>
                           <item>In another clinical study, 16 adolescent subjects (12 to less than 17 years old) with moderate to severe plaque psoriasis involving 10% or more of their body surtace area applied a maximum of approximately 50 grams of ULTRAVATE lotion to affected areas twice daily for two weeks. Of the 14 subjects evaluated for HPA axis suppression, adrenal suppression occurred in 1 subject (7%) which recovered upon retest 
   <content styleCode="italics">[see Clinical Pharmacology (12.2)]</content>.
  </item>
                        </list>
                        <paragraph>Because of the potential for systemic absorption, use of topical corticosteroids, including ULTRAVATE lotion, may require that patients be evaluated periodically for evidence of HPA axis suppression. Factors that predispose a patient using a topical corticosteroid to HPA axis suppression include the use of more potent corticosteroids, use over large surtace areas, prolonged use, occlusive use, use on an altered skin barrier, concomitant use of multiple corticosteroid-containing products, liver failure, and young age. An ACTH stimulation test may be helpful in evaluating patients for HPA axis suppression.If HPA axis suppression is documented, attempt to gradually withdraw the drug, reduce the frequency of application, or substitute a less potent steroid. Manifestations of adrenal insufficiency may require supplemental systemic corticosteroids. Recovery of HPA axis function is generally prompt and complete upon discontinuation of topical corticosteroids.Systemic effects of topical corticosteroids may also include Cushing's syndrome, hyperglycemia, and glucosuria. Use of more than one corticosteroid-containing product at the same time may increase the total systemic exposure to topical corticosteroids. Pediatric patients may be more susceptible than adults to systemic toxicity from the use of topical corticosteroids due to their larger surtace-to-body mass ratios [see Use in Specific Populations (8.4)].</paragraph>
                     </text>
                     <effectiveTime value="20250406"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.2">
                     <id root="32225bd7-54c3-93da-e063-6394a90aadc5"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2 Local Adverse Reactions</title>
                     <text>
                        <paragraph>Local adverse reactions from topical corticosteroids may include atrophy, striae, telangiectasias, burning, itching, irritation, dryness, folliculitis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, secondary infection, and miliaria. These may be more likely to occur with occlusive use, prolonged use, or use of higher potency corticosteroids, including ULTRAVATE lotion. Some local adverse reactions may be irreversible.</paragraph>
                     </text>
                     <effectiveTime value="20250406"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.3">
                     <id root="32225bd7-54c4-93da-e063-6394a90aadc5"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3 Ophthalmic Adverse Reactions</title>
                     <text>
                        <paragraph>Use of topical corticosteroids may increase the risk of posterior subcapsular cataracts and glaucoma. Cataracts and glaucoma have been reported in postmarketing experience with the use of topical corticosteroid products.</paragraph>
                        <paragraph>Advise patients to report any visual symptoms and consider referral to an ophthalmologist for evaluation.</paragraph>
                     </text>
                     <effectiveTime value="20250406"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.4">
                     <id root="32225bd7-54c5-93da-e063-6394a90aadc5"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.4 Concomitant Skin Infections</title>
                     <text>
                        <paragraph>Use an appropriate antimicrobial agent if a skin infection is present or develops. If a favorable response does not occur promptly, discontinue use of ULTRAVATE lotion until the infection has been adequately treated.</paragraph>
                     </text>
                     <effectiveTime value="20250406"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.5">
                     <id root="32225bd7-54c6-93da-e063-6394a90aadc5"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.5 Allergic Contact Dermatitis</title>
                     <text>
                        <paragraph>Allergic contact dermatitis with corticosteroids is usually diagnosed by observing failure to heal rather than noting a clinical exacerbation. Consider confirmation of a clinical diagnosis of allergic contact dermatitis by appropriate patch testing. Discontinue ULTRAVATE lotion if allergic contact dermatitis is established.</paragraph>
                     </text>
                     <effectiveTime value="20250406"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S6">
               <id root="32225bd7-54c7-93da-e063-6394a90aadc5"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <text/>
               <effectiveTime value="20250406"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>The most commonly reported adverse reactions (≥1%) are telangiectasia, application site atrophy, and headache. (
 
    <linkHtml href="#S6.1">6.1</linkHtml>)

   </paragraph>
                        <paragraph/>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact LAcer Pharma, LLC at 1-888-403-8874 or FDA at 1-800-FDA-1088 or
  
     <content styleCode="italics">
                                 <content styleCode="underline">www.fda.gov/medwatch</content>
                              </content>.
 
    </content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S6.1">
                     <id root="3222ebfc-7f80-ccee-e063-6394a90a3659"/>
                     <code code="90374-0" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL TRIALS EXPERIENCE SECTION"/>
                     <title>6.1 Clinical Trials Experience</title>
                     <text>
                        <paragraph/>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. </paragraph>
                        <paragraph>During randomized, controlled, blinded clinical trials 277 adults with plaque psoriasis were treated with ULTRAVATE lotion twice daily for up to two weeks (up to approximately 50 grams/week).</paragraph>
                        <paragraph>Table 1 presents adverse reactions that occured in at least 1% of subjects treated with ULTRAVATE lotion twice daily for up to two weeks, and more frequently than in vehicle-treated subjects. </paragraph>
                        <table width="65%">
                           <caption>Table 1: Adverse Reactions Occurring in ≥ 1% of Subjects Treated with ULTRAVATE Lotion for up to Two Weeks</caption>
                           <colgroup>
                              <col align="left" valign="middle" width="60%"/>
                              <col align="center" valign="middle" width="20%"/>
                              <col align="center" valign="middle" width="20%"/>
                           </colgroup>
                           <thead>
                              <tr styleCode="Botrule First">
                                 <th align="left" styleCode="Lrule Rrule"/>
                                 <th align="center" styleCode="Rrule">ULTRAVATE Lotion
     <br/>
			(N=277)
    </th>
                                 <th align="center" styleCode="Rrule">Vehicle Lotion
     <br/>
			(N=259)
    </th>
                              </tr>
                              <tr>
                                 <th align="left" styleCode="Lrule Rrule">
                                    <content styleCode="italics">Adverse Reaction</content>
                                 </th>
                                 <th align="center" styleCode="Rrule">%</th>
                                 <th align="center" styleCode="Rrule">%</th>
                              </tr>
                           </thead>
                           <tfoot>
                              <tr styleCode="First Last">
                                 <td align="left" colspan="3"/>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr styleCode="Botrule First">
                                 <td align="left" styleCode="Lrule Rrule">Telangiectasia</td>
                                 <td align="center" styleCode="Rrule">1%</td>
                                 <td align="center" styleCode="Rrule">0%</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="left" styleCode="Lrule Rrule">Application site atrophy</td>
                                 <td align="center" styleCode="Rrule">1%</td>
                                 <td align="center" styleCode="Rrule">&lt;1%</td>
                              </tr>
                              <tr>
                                 <td align="left" styleCode="Lrule Rrule">Headache</td>
                                 <td align="center" styleCode="Rrule">1%</td>
                                 <td align="center" styleCode="Rrule">&lt;1%</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph/>
                        <paragraph>Less common dverse reactions (incidence less than 1% but greater than 0.1%) that occured in subjects treated with ULTRAVATE lotion included application site discoloration, herpes zoster, influenza, nasopharyngitis, otitis media acute, throat infection, wound, and increased blood pressure. </paragraph>
                     </text>
                     <effectiveTime value="20250406"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S8">
               <id root="32225bd7-54c9-93da-e063-6394a90aadc5"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20250406"/>
               <component>
                  <section ID="S8.1">
                     <id root="32225bd7-54ca-93da-e063-6394a90aadc5"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <effectiveTime value="20250406"/>
                     <component>
                        <section ID="id_link_3222fe49-b1fa-4918-e063-6294a90a9305">
                           <id root="3222e67f-c9e2-93f7-e063-6294a90a136d"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>There are no available data on Ultravate lotion use in pregnant women to inform a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. Published data report an increased risk of low birthweight with the use of greater than 300 grams of potent or very potent topical corticosteroid during pregnancy. In animal reproduction studies, halobetasol propionate administered systemically during organogenesis to pregnant rats at 13 and 33 times the human topical dose and to pregnant rabbits at 3 times the human topical dose resulted in teratogenic and embryotoxic effects [see Data]. The clinical relevance of the animal findings is not clear.</paragraph>
                              <paragraph>The background risk of major birth defects and miscarriage for the indicated population are unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.</paragraph>
                           </text>
                           <effectiveTime value="20250406"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="32225bd7-54cc-93da-e063-6394a90aadc5"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Data</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20250406"/>
                           <component>
                              <section>
                                 <id root="32225bd7-54cd-93da-e063-6394a90aadc5"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Human Data</content>
                                       <br/>  Multiple observational studies found no significant associations between maternal use of topical corticosteroids of any potency and congenital malformations, preterm delivery, or fetal mortality. However, when the dispensed amount of potent or very potent topical corticosteroid exceeded 300 g during the entire pregnancy, use was associated with an increase in low birth weight infants.

 </paragraph>
                                 </text>
                                 <effectiveTime value="20250406"/>
                              </section>
                           </component>
                           <component>
                              <section ID="id_link_3222ef53-4a9b-83a7-e063-6294a90acd78">
                                 <id root="3222ef53-4a9a-83a7-e063-6294a90acd78"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Animal Data</content>
                                    </paragraph>
                                    <paragraph>Halobetasol propionate has been shown to be teratogenic in rats and rabbits when given systemically during organogenesis at doses of 0.04 to 0.1 mg/kg/day in rats and 0.01 mg/kg/day in rabbits. These doses are approximately 13, 33, and 3 times, respectively, the human topical dose of halobetasol propionate, 0.05%. Halobetasol propionate was embryotoxic in rabbits but not in rats.Cleft palate was observed in both rats and rabbits. Omphalocele was seen in rats, but not in rabbits.</paragraph>
                                 </text>
                                 <effectiveTime value="20250406"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.2a">
                     <id root="32225bd7-54cf-93da-e063-6394a90aadc5"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>8.2 Lactation</title>
                     <effectiveTime value="20250406"/>
                     <component>
                        <section>
                           <id root="32225bd7-54d0-93da-e063-6394a90aadc5"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk Summary</content>
                              </paragraph>
                              <paragraph>There are no data on the presence of halobetasol propionate or its metabolites in human milk, the effects on the breastted infant, or the effects on milk production after topical application to women who are breastteeding.</paragraph>
                              <paragraph>Systemically administered corticosteroids appear in human milk and could suppress growth, intertere with endogenous corticosteroid production, or cause other untoward effects. It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in human milk. The developmental and health benefits of breastteeding should be considered along with the mother's clinical need for UL TRAVATE lotion and any potentialadverse effects on the breastted infant from ULTRAVATE lotion or from the underlying maternal condition.</paragraph>
                           </text>
                           <effectiveTime value="20250406"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="32225bd7-54d1-93da-e063-6394a90aadc5"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Clinical Considerations</content>
                              </paragraph>
                              <paragraph>Advise breastfeeding women not to apply ULTRAVATE lotion directly to the nipple and areola to avoid direct infant exposure.</paragraph>
                           </text>
                           <effectiveTime value="20250406"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.4">
                     <id root="32225bd7-54d2-93da-e063-6394a90aadc5"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph>Safety and effectiveness of ULTRAVATE lotion for the treatment of moderate to severe plaque psoriasis have been established in patients 12 years of age and older. It is supported by evidence from adequate and well-controlled trials in adults and from one uncontrolled safety trial in 16 adolescents (12 to less than 17 years of age). Adolescent patients with moderate to severe plaque psoriasis covering a minimum of 10% of the total body surface area were treated twice daily for 2 weeks with ULTRAVATE lotion. Hypothalamic-pituitary adrenal (HPA) axis function (ACTH stimulation test) was evaluated in a subset of 14 patients. After 2 weeks of treatment, 1 of 14 patients (7%) experienced laboratory evidence of adrenal suppression (i.e., cortisol serum level of sl 8 μg/dL) that recovered upon retest. No other adverse reactions were reported in the study.</paragraph>
                        <paragraph>Because of higher skin surtace area to body mass ratios, pediatric patients are at a greater risk than adults of HPA axis suppression and Cushing's syndrome when they are treated with topical corticosteroids. They are therefore also at greater risk of adrenal insufficiency during or after withdrawal of treatment. Adverse reactions including striae have been reported with use of topical corticosteroids in infants and children.</paragraph>
                        <paragraph>HPA axis suppression, Cushing's syndrome, linear growth retardation, delayed weight gain, and intracranial hypertension have been reported in children receiving topical corticosteroids. Manifestations of adrenal suppression in children include low plasma cortisol levels and an absence of response to ACTH stimulation. Manifestations of intracranial hypertension include bulging fontanelles, headaches, and bilateral papilledema.</paragraph>
                     </text>
                     <effectiveTime value="20250406"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.5">
                     <id root="32225bd7-54d3-93da-e063-6394a90aadc5"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph>Clinical studies with ULTRAVATE lotion included 89 subjects aged 65 years and over. No overall differences in safety or effectiveness were observed between these subjects and those younger than 65 years. Clinical studies of ULTRAVATE lotion did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects.</paragraph>
                     </text>
                     <effectiveTime value="20250406"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S10">
               <id root="32225bd7-54d4-93da-e063-6394a90aadc5"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE</title>
               <text>
                  <paragraph>Topically applied ULTRAVATE lotion can be absorbed in sufficient amounts to produce systemic effects [see
 
  <content styleCode="italics">
                        <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>
                     </content>].

 </paragraph>
               </text>
               <effectiveTime value="20250406"/>
            </section>
         </component>
         <component>
            <section ID="S11">
               <id root="32225bd7-54d5-93da-e063-6394a90aadc5"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph>ULTRAVATE (halobetasol propionate) lotion, 0.05% for topical use contains a corticosteroid, halobetasol propionate. The chemical name of halobetasol propionate is 21­ chloro-6α, 9-difluoro-11β, 17-dihydroxy-16β-methylpregna-1, 4-diene-3,20-dione 17­ propionate. Halobetasol propionate is a white to off-white crystalline powder with a molecular weight of 484.96 and a molecular formula of C
 
  <sub>25</sub>H
 
  <sub>31</sub>ClF
 
  <sub>2</sub>O
 
  <sub>5</sub>. It is practically insoluble in water and freely soluble in dichloromethane and in acetone. It has the following structural formula:

 </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM1"/>
                  </paragraph>
                  <paragraph>Each gram of ULTRAVATE lotion contains 0.5 mg of halobetasol propionate in a white to off-white lotion base consisting of diisopropyl adipate, octyldodecanol, ceteth-20, poloxamer 407, cetyl alcohol, stearyl alcohol, propylparaben, butylparaben, propylene glycol, glycerin, carbomer homopolymer, sodium hydroxide, and water.</paragraph>
               </text>
               <effectiveTime value="20250406"/>
               <component>
                  <observationMedia ID="MM1">
                     <text>Chemical Structure</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="halobestasol-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="S12">
               <id root="32225bd7-54d6-93da-e063-6394a90aadc5"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20250406"/>
               <component>
                  <section ID="S12.1">
                     <id root="32225bd7-54d7-93da-e063-6394a90aadc5"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph>Corticosteroids play a role in cellular signaling, immune function, inflammation, and protein regulation; however, the precise mechanism of action in plaque psoriasis is unknown.</paragraph>
                     </text>
                     <effectiveTime value="20250406"/>
                  </section>
               </component>
               <component>
                  <section ID="S12.2">
                     <id root="32225bd7-54d8-93da-e063-6394a90aadc5"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics</title>
                     <effectiveTime value="20250406"/>
                     <component>
                        <section>
                           <id root="32225bd7-54d9-93da-e063-6394a90aadc5"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="italics">Vasoconstriction:</content>
                                 <br/>  A vasoconstrictor assay in healthy subjects with ULTRAVATE lotion indicated that the formulation is in the super-high range of potency as compared to other topical corticosteroids; however, similar blanching scores do not necessarily imply therapeutic equivalence.

 </paragraph>
                              <paragraph>
                                 <content styleCode="italics">Hypothalamic-Pituitaty-Adrenal (HPA) Axis Suppression:</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="italics"/>The potential for hypothalamic-pituitary adrenal (HPA) suppression was evaluated in the following two studies. In both studies, the criteria for HPA-axis suppression was a serum cortisol level of less than or equal to 18 micrograms per deciliter 30 minutes after stimulation with cosyntropin (adrenocorticotropic hormone, ACTH). In the first study, ULTRAVATE lotion was applied to20 adult subjects with moderate to severe plaque psoriasis. A mean dose of 3.5 grams ULTRAVATE lotion was applied twice daily for two weeks and produced HPA axis suppression in 5 of 20 (25%) subjects. The effects of HPA axis suppression were reversible on retesting at least four weeks after discontinuation of the treatment. In the second study, ULTRAVATE lotion was applied to 16 adolescent subjects 12 years to less than 17 years of age with moderate to severe plaque psoriasis affecting a mean body surtace area of 11.5% (range from 10% to 14%). The mean dose was 3.6 grams applied twice daily for two weeks. A subset of 14 of the 16 completed subjects had evaluable ACTH stimulation tests, and HPA axis suppression was observed in 1 of these 14 subjects (7%). In the second study also, the effects of HPA axis suppression were reversible on retesting at least four weeks after discontinuation of the treatment.

 </paragraph>
                           </text>
                           <effectiveTime value="20250406"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S12.3">
                     <id root="32225bd7-54da-93da-e063-6394a90aadc5"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <text>
                        <paragraph>The extent of percutaneous absorption of topical corticosteroids is determined by many factors, including the vehicle, the integrity of the epidermal barrier, and the use of occlusive dressings. Topical corticosteroids can be absorbed from normal intact skin. Inflammation and/or other disease processes in the skin may increase percutaneous absorption.</paragraph>
                        <paragraph>In the HPA clinical study /see Clinical Pharmacology (12.2)1, pharmacokinetics was evaluated in a subgroup of 12 adult subjects. On Day 8, blood was taken just prior to and at 1, 2, 4, 6, 8, and 12 hours following the last application. Plasma concentration of halobetasol propionate (HBP) was measurable in all subjects. Based on the geometric mean plasma concentrations at 12 hours post-application across time, steady-state was achieved by Day 8. The mean (±standard deviation) C
 
  <sub>max</sub>concentrations for ULTRAVATE lotion on Day 8 was 201.1 ± 157.5 pg/ml, with the corresponding median T
 
  <sub>max</sub>value of 3 hours (range O - 6 hours); mean area under the halobetasol propionate concentration versus time curve over the dosing interval (AUCt) was 1632 ± 1147 pg•h/ml.

 </paragraph>
                        <paragraph>
                           <content styleCode="italics">
                              <content styleCode="underline">Specific Populations</content>
                           </content>
                           <br/>
                           <content styleCode="italics">Pediatric Patients</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics"/>In the pediatric HPA study
 
  <content styleCode="italics">[see Clinical Pharmacology (12.2)]</content>, trough plasma concentrations of HBP were measured on Day 8 and Day 15 in a subset of 14 subjects. The HBP levels in the plasma were below the quantification limit (20 pg/ml) for all subjects at all time points with the exception of one subject at Day 15 (trough concentration of HBP of 28.2 pg/ml).

 </paragraph>
                     </text>
                     <effectiveTime value="20250406"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S13">
               <id root="32225bd7-54db-93da-e063-6394a90aadc5"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20250406"/>
               <component>
                  <section ID="S13.1">
                     <id root="32225bd7-54dc-93da-e063-6394a90aadc5"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph>Long-term animal studies have not been performed to evaluate the carcinogenic potential of halobetasol propionate.</paragraph>
                        <paragraph>In a 90-day repeat-dose toxicity study in rats, topical administration of Halobetasol Propionate Topical Foam at dose concentrations from 0.005% to 0.05% or from 0.011 to 0.11 mg/kg/day of halobetasol propionate resulted in a toxicity profile consistent with long-term exposure to corticosteroids including adrenal atrophy, histopathological changes in several organ systems indicative of severe immune suppression, and opportunistic fungal and bacterial infections. A no observable adverse effect level could not be determined in this study. Although the clinical relevance of the findings in animals to humans is not clear, sustained glucocorticoid-related immune suppression may increase the risk of infection and possibly the risk of carcinogenesis.</paragraph>
                        <paragraph>Halobetasol propionate was not found to be genotoxic in the Ames/Salmonella assay, in the Chinese hamster CHO/HGPRT assay, in the mouse micronucleus test, in the sister chromatid exchange test in somatic cells of the Chinese hamster, or in the chromosome aberration test in somatic cells of Chinese hamsters. Positive mutagenicity effects were observed in two genotoxicity assays: Chinese hamster nuclear anomaly test and mouse lymphoma gene mutation assay in vitro.</paragraph>
                        <paragraph>Studies in the rat following oral administration at dose levels up to 0.05 mg/kg/day indicated no impairment of fertility or general reproductive performance.</paragraph>
                     </text>
                     <effectiveTime value="20250406"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S14">
               <id root="32232262-0d79-8de3-e063-6294a90a3bfe"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES</title>
               <text>
                  <paragraph/>
                  <paragraph>ULTRAVATE lotion was evaluated for the treatment of moderate to severe plaque psoriasis in two multicenter, randomized, doble-blind, vehicle-controlled trials. </paragraph>
                  <paragraph>These trials were conducted in 443 subjects 18 years of age and older with plaque psoriasis involving between 2% and 12% body surface area. Baseline disease severity was determined using a static, five-level global evaluation scale, on which a subject scored either moderate or severe. Overall, 57% of subjects were male and 86% were Caucasian.</paragraph>
                  <paragraph>Subjects applied ULTRAVATE lotion or vehicle to all affected areas twice daily for up to 14 consecutive days. </paragraph>
                  <paragraph>The primary measure of efficacy was Overall Treatment Success, defined as the proportion of subjects who were cleared or almost cleared with at least a two grade improvement from baseline at Week 2 (end of treatment). Table 2 presents these results. </paragraph>
                  <table width="65%">
                     <caption>Table 2: Overall Treatment Success in Subjects with Plaque Psoriasis at Week 2</caption>
                     <colgroup>
                        <col align="left" valign="middle" width="26%"/>
                        <col align="center" valign="middle" width="19%"/>
                        <col align="center" valign="middle" width="18%"/>
                        <col align="center" valign="middle" width="19%"/>
                        <col align="center" valign="middle" width="18%"/>
                     </colgroup>
                     <thead>
                        <tr styleCode="Botrule First">
                           <th align="left" styleCode="Lrule Rrule"/>
                           <th align="center" colspan="2" styleCode="Rrule" valign="top">Study 1</th>
                           <th align="center" colspan="2" styleCode="Rrule" valign="top">Study 2</th>
                        </tr>
                        <tr>
                           <th align="left" styleCode="Lrule Rrule"/>
                           <th align="center" styleCode="Rrule">ULTRAVATE Lotion
     <br/>
			N=110
    </th>
                           <th align="center" styleCode="Rrule">Vehicle Lotion
     <br/>
			N=76
    </th>
                           <th align="center" styleCode="Rrule">ULTRAVATE Lotion
     <br/>
			N=110
    </th>
                           <th align="center" styleCode="Rrule">Vehicle Lotion
     <br/>
			N=112
    </th>
                        </tr>
                     </thead>
                     <tbody>
                        <tr styleCode="Botrule First Last">
                           <td align="left" styleCode="Lrule Rrule">Overall Treatment Success
     <footnote ID="fn_26156376-e85b-4f1d-b955-520900a0492e">Subject whose condition was cleared or almost cleared of all signs of psoriasis and with at least a two grade improvement from baseline. </footnote>
                           </td>
                           <td align="center" styleCode="Rrule">49 (44.5%)</td>
                           <td align="center" styleCode="Rrule">7 (6.3%)</td>
                           <td align="center" styleCode="Rrule">49 (44.5%)</td>
                           <td align="center" styleCode="Rrule">8 (7.1%)</td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>The secondary measures of efficacy were Treatment Success for individual signs of psoriasis (scaling, erythema, and plaque
  <br/>
elevation) at the end of treatment (see Table 3).
 </paragraph>
                  <table width="100%">
                     <caption>Table 3: Individual Signs Treatment Success in Subjects with Plaque Psoriasis at Week 2</caption>
                     <tbody>
                        <tr>
                           <td/>
                           <td colspan="2">Study 1</td>
                           <td colspan="2">Study 2</td>
                        </tr>
                        <tr>
                           <td>Treatment Success
     <footnote ID="fn_0988e682-a2d7-4596-bb92-6d04d3b66b70">Subjects who were cleared or almost cleared of the designated clinical sign with at least a two grade improvement from baseline. </footnote>
                           </td>
                           <td>ULTRAVATE Lotion N=10</td>
                           <td>Vehicle Lotion N=111</td>
                           <td>ULTRAVATE Lotion N=110</td>
                           <td>Vehicle Lotio N=112</td>
                        </tr>
                        <tr>
                           <td>Scaling</td>
                           <td>61 (55.5%)</td>
                           <td>12 (10.8%)</td>
                           <td>65 (59.1%)</td>
                           <td>11 (9.8%)</td>
                        </tr>
                        <tr>
                           <td>Erythema</td>
                           <td>40 (36.4%)</td>
                           <td>8 (7.2%)</td>
                           <td>48 (43.6%)</td>
                           <td>12 (10.7%)</td>
                        </tr>
                        <tr>
                           <td>Plaque Elevation</td>
                           <td>50 (45.5%)</td>
                           <td>9 (8.1%)</td>
                           <td>48 (43.6%)</td>
                           <td>9 (8.0%)</td>
                        </tr>
                     </tbody>
                  </table>
               </text>
               <effectiveTime value="20250406"/>
            </section>
         </component>
         <component>
            <section ID="S16">
               <id root="32225bd7-54de-93da-e063-6394a90aadc5"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <effectiveTime value="20250406"/>
               <component>
                  <section ID="S16.1">
                     <id root="32225bd7-54df-93da-e063-6394a90aadc5"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>ULTRAVATE lotion, 0.05 % is white to off-white lotion. It is supplied in an oval tapered white high-density polyethylene bottle with a white polypropylene disc cap. Each bottle contains 60 ml (59 g) of ULTRAVATE lotion.</paragraph>
                        <paragraph>NOC 73159-008-60 60 ml (59 g) bottle</paragraph>
                        <paragraph>Store at 25'C (77'F); excursions permitted to 15°G and 30°G (59° F to 86°F) [see USP Controlled Room Temperature]. Do not freeze.</paragraph>
                     </text>
                     <effectiveTime value="20250406"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S17">
               <id root="32225bd7-54e0-93da-e063-6394a90aadc5"/>
               <code code="88436-1" codeSystem="2.16.840.1.113883.6.1" displayName="PATIENT COUNSELING INFORMATION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph>Advise the patient to read the FDA-approved patient labeling (Patient Information).</paragraph>
                  <paragraph>Advise patients using ULTRAVATE lotion of the following information and instructions:</paragraph>
                  <paragraph>
                     <content styleCode="underline">Important Administration Instructions</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline"/>Instruct patients to discontinue ULTRAVATE lotion when psoriasis is controlled. ULTRAVATE lotion should not be used for longer than 2 weeks. Advise patients to contact the physician if no improvement is seen within 2 weeks. Inform patients that total dosage should not exceed 50 grams per week
 
  <content styleCode="italics">[see Dosage and Administration (2)]</content>.

 </paragraph>
                  <paragraph>Instruct patients to avoid bandaging, wrapping or otherwise occluding the treatment area(s), unless directed by physician. Advise patients to avoid use on the face, scalp, groin, or axillae
 
  <content styleCode="italics">[see Dosage and Administration (2)]</content>.

 </paragraph>
                  <paragraph>
                     <content styleCode="underline">Effects on Endocrine System</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline"/>UL TRAVATE lotion may cause HPA axis suppression. Advise patients that use of UL TRAVATE lotion, may require periodic evaluation for HPA axis suppression. Advise patients to avoid use of multiple corticosteroid-containing products
 
  <content styleCode="italics">[see Warnings and Precautions (5.1)]</content>.

 </paragraph>
                  <paragraph>
                     <content styleCode="underline">Local Adverse Reactions</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline"/>Inform patients that topical corticosteroids may cause local adverse reactions, some of which may be irreversible. These reactions may be more likely to occur with occlusive use, prolonged use or use of higher potency comcosteroids, including ULTRAVATE lotion
 
  <content styleCode="italics">[see Warnings and Precautions (5.2)]</content>.

 </paragraph>
                  <paragraph>Breastteeding women should not apply ULTRAVATE lotion directly to the nipple and areola to avoid directly exposing the infant
 
  <content styleCode="italics">[see Lactation (8.2)].</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="italics"/>
                  </paragraph>
               </text>
               <effectiveTime value="20250406"/>
            </section>
         </component>
         <component>
            <section>
               <id root="32225bd7-54e1-93da-e063-6394a90aadc5"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <text>
                  <paragraph>ULTRAVATE is a trademark of Lacer Pharma, LLC 
  <br/>  Manufactured by: Ferndale Laboratories, Inc., Ferndale, Ml 48220 
  <br/>  Distributed by: Lacer Pharma, LLC, Biloxi, MS 39532 
  <br/>  U.S. Patent 8,962,028 
  <br/>  Document Control No. 69311. 
  <br/>  Rev.: 0125
 </paragraph>
               </text>
               <effectiveTime value="20250406"/>
            </section>
         </component>
         <component>
            <section ID="id_link_3222b143-0db7-4f40-e063-6294a90a1727">
               <id root="32225ecb-1cd4-9ad4-e063-6394a90a8a58"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 50 g Canister Carton</title>
               <text>
                  <paragraph>NDC 73159-008-60</paragraph>
                  <paragraph>ULTRAVATE lotion, 0.05%</paragraph>
                  <paragraph>For topical use only.</paragraph>
                  <paragraph>Rx ONLY</paragraph>
                  <paragraph>Net Wt. 60 mL (59 g) bottle</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="img_32222dd0-bd6a-004b-e063-6294a90a06f5"/>
                  </paragraph>
                  <paragraph/>
               </text>
               <effectiveTime value="20230331"/>
               <component>
                  <observationMedia ID="img_32222dd0-bd6a-004b-e063-6294a90a06f5">
                     <text>Carton Image</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="Ultravate Carton.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>